Exhibit 99.1

        Greatbatch, Inc. Announces Facility Consolidation Plan

    CLARENCE, N.Y.--(BUSINESS WIRE)--Nov. 16, 2005--Greatbatch, Inc.
(the "Company") (NYSE:GB) announced today a plan for the closure of
both its Columbia, MD. facility and its Fremont, CA Advanced Research
Laboratory ("ARL"). As part of the Company's continuing efforts to
decrease its cost structure and improve manufacturing efficiencies,
management approved a plan on November 14, 2005, to consolidate the
feedthrough manufacturing and specialty coating operations in Columbia
into its Tijuana, Mexico facility. Additionally, the research,
development and engineering and product development (RD&E) functions
at Columbia and Fremont will relocate to the Technology Center located
in Clarence, New York.
    The total estimated cost for these two facility consolidation
plans is anticipated to be between $7.9 million and $8.3 million. The
Company expects to incur this additional cost over the next 18 months.
The major categories of costs to be incurred include the following:

    --  Costs related to the shut-down of the Columbia and Fremont
        facilities

        --  Severance and retention - $2.7 to $2.8 million

        --  Accelerated depreciation/Asset write-offs - $0.7 million

        --  Other - $0.2 to $0.3 million

    --  Costs related to the move and consolidation of work into
        Tijuana

        --  Production inefficiencies and revalidation - $0.4 to $0.5
            million

        --  Relocation and moving expenses - $0.2 million

        --  Personnel costs (including travel, training and duplicate
            wages) - $2.0 to $2.1 million

        --  Other - including asset write-offs - $0.1 million

    --  Cost related to the move and consolidation of the RD&E
        functions to Clarence, NY.

        --  Personnel costs (including travel, recruiting, and
            duplicate wages) - $1.5 million

        --  Other - $0.1 million

    All categories of costs are considered to be future cash
expenditures, except accelerated depreciation and asset write-offs.
    Once the moves are completed, the Company anticipates annual
structural cost savings in the range of $5.0 to $6.0 million.
    During the fourth quarter of 2005, the Company expects to incur
pre-tax charges of $2.0 million, or $0.06 per share after-tax
pertaining to the aforementioned personnel and moving expenses. Based
on this information, the Company has revised its 2005 full year
earnings per share guidance in accordance with United States generally
accepted accounting principles to be in the range of $.39 to $.49 per
share from the previously issued $.45 to $.55 per share.

    Forward-Looking Statements

    Some of the statements in this press release, and other written
and oral statements made from time to time by the company and its
representatives are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and section 21E
of the Securities Exchange Act of 1934, as amended, and involve a
number of risks and uncertainties. These statements can be identified
by terminology such as "may," "will," "should," "could," "expects,"
"intends," "plans," "anticipates," "believes," "estimates,"
"predicts," "potential" or "continue" or the negative of these terms
or other comparable terminology. These statements are based on the
Company's current expectations. The Company's actual results could
differ materially from those stated or implied in such forward-looking
statements. Risks and uncertainties that could cause actual results to
differ materially from those stated or implied by such forward-looking
statements include, among others, the following matters affecting the
Company: dependence upon a limited number of customers; customer
ordering patterns; product obsolescence; inability to market current
or future products; pricing pressure from customers; reliance on third
party suppliers for raw materials, products and subcomponents;
fluctuating operating results; inability to maintain high quality
standards for our products; challenges to our intellectual property
rights; product liability claims; inability to successfully consummate
and integrate acquisitions; unsuccessful expansion into new markets;
competition; inability to obtain licenses to key technology;
regulatory changes or consolidation in the healthcare industry; and
other risks and uncertainties described in the Company's Annual Report
on Form 10-K, including Exhibit 99.1 thereto, and in other periodic
filings with the Securities and Exchange Commission. The Company
assumes no obligation to update forward-looking information in this
press release whether to reflect changed assumptions, the occurrence
of unanticipated events or changes in future operating results,
financial conditions or prospects, or otherwise.

    About Greatbatch, Inc.

    Greatbatch, Inc., is a leading developer and manufacturer of
critical components used in implantable medical devices and other
technically demanding applications. Additional information about the
Company is available at www.greatbatch.com.

    CONTACT: Greatbatch, Inc.
             Anthony W. Borowicz, 716-759-5809
             tborowicz@greatbatch.com